Article and Video CATEGORIES
Our next webinar, at 6 PM Eastern/3 PM Pacific on Wednesday, December 7th, will feature Dr Mark Millard, Medical Director of the Baylor Martha Foster Lung Care Center and Professor of Pulmonology at Baylor University Medical Center, speaking on the history of tobacco's association with lung cancer, and the current tools to help people quit smoking. Of course, the association of smoking with lung cancer is a sensitive topic, leading to all too much stigma and blame. It doesn't cause all lung cancer, but it is the leading risk factor, and tobacco is also associated with markedly increased risk of other cancers and many other medical problems. Dr. Millard provides a truly interesting and thoughtful review of the subject.
He'll also cover the range of practical options available to help people quit smoking. We should all be aware of the powerful addiction caused by nicotine (yes, my own mother has been a smoker for more than 50 years, and not because she doesn't want to quit), but people can beat it: This lowers their risk of lung cancer and other medical issues readily, and for those fighting lung cancer, it can improve their treatment outcomes. It's never too late to quit, so learn more about the options, for yourself or someone you care about.
The approximately 30-40 minute presentation will be follwed by a question and answer session, so feel free to jump in with a relevant question.
This webinar is part of an ongoing series produced by GRACE in partnership with the LUNGevity Foundation. All of the live webinars are free (learn more and register here), and they are all edited into free podcasts later.
We hope you'll join us on December 7th.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…